Project Details
Description
Summary
Nigral dopaminergic (DA) neurons (i.e. A9 DA neurons) that are lost in Parkinson’s
disease (PD) have autonomous pacemaking action potentials, massive axon arborization, and
expression of GIRK2, but not calbindin. Despite the significant progress in the differentiation of
human embryonic stem cells (hESCs) to midbrain DA neurons, it has been difficult to generate
A9 type DA neurons, particularly from human induced pluripotent stem cells (iPSCs). We
developed an improved floorplate-based method to differentiate patient-specific iPSCs to
midbrain DA neurons that expressed appropriate markers for A9 type cells and exhibited
calcium channel-dependent autonomous pacemaking activities independent of glutamatergic
inputs. These iPSC-derived DA neurons extended elaborate neuronal fibers when grafted to 6-
OHDA-lesioned rats and restored locomotor deficits. We have generated isogenic pairs of
iPSCs by repairing parkin mutations in patient cells and by introducing parkin mutations to
control cells. Using these isogenic iPSCs, we will study how parkin mutations mechanistically
disrupt the precision of dopaminergic transmission in three different preparations: monolayer
cultures, brain organoids, and graft in 6-OHDA-lesioned rat brains. The three novel approaches
will enable us to approximate the situation in the brains of PD patients. The study will bridge the
gap between mechanistic understanding of the cellular function of parkin and its role in PD
pathophysiology that is directly linked to the motor symptoms. The results will stimulate the
development of disease-modifying therapies of Parkinson's disease .
| Status | Finished |
|---|---|
| Effective start/end date | 09/1/18 → 03/31/23 |
Funding
- National Inst of Neurological Disorders & Stroke: $1,998,721.74
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.